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Introduction
============

Untreated stage I lung cancer generally portends a poor prognosis, with median overall survival (OS) of 9--14 months \[[@REF1]\]. However in elderly populations, particularly those with significant comorbidities, treatment decisions must weigh a cancer's aggressiveness with competing risks of death. There are an increasing number of retrospective studies noting the safety and efficacy of stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC) in the elderly \[[@REF2]-[@REF7]\]. However, radiation therapy (RT)-associated morbidity could negatively impact quality-of-life (QOL), and, although rare, SABR has been implicated in serious complications \[[@REF8]-[@REF10]\], which can be more impactful for those with waning baseline QOL.

Lung cancer screening using low-dose computed tomography (CT) scans was associated with a 20% reduction in mortality in the National Lung Screening Trial Research Team (NLST) trial \[[@REF11]\]. Although less than 9% of the patient population in the NLST trial was \>70 years old, the US Preventive Services Task Force advocates lung cancer screening and treatment for patients up to 80 years old \[[@REF12]\]. With increased screening, it can be expected that an increasing number of elderly patients with significant comorbidities will be found to have early-stage NSCLC; however, survival benefit decreases with increasing age. Of note, over 95% of patients in the NLST had negative biopsies, putting many patients without cancer at risk for procedural complications \[[@REF11]\]. Additionally, there has been an associated overtreatment rate of \~18% \[[@REF13]\]. Overtreatment may be even more prevalent in elderly populations, where larger proportions of asymptomatic nodules are found incidentally \[[@REF14]\].

Prognostic factors, i.e., tumor volume doubling time (VDT), positron emission tomography \[[@REF15]\] maximum standardized uptake value (PET SUV), and solid component size \[[@REF16]\], may improve predictions regarding who would be best managed with active surveillance (AS): AS is defined as following patients closely with intent to provide definitive treatment, if necessary. This approach would allow frailer, older individuals to avoid, or delay, treatment-associated toxicity without compromising tumor treatability or cancer outcomes. Here, we report the first series to our knowledge investigating AS for elderly patients with incidentally discovered medically inoperable stage IA lung cancer.

Materials and methods
=====================

Twelve consecutive patients were retrospectively reviewed with medically inoperable pathologically confirmed stage IA, T1N0M0 lung cancer \[[@REF17]\], who chose AS between 2014 and 2017, with treatment reserved for clear radiographic progression of disease. Follow-up chest CTs were recommended as frequently as every two months, and up to every six months if disease was approximately stable. Clinical data included Karnofsky Performance Score (KPS), Charlson-Deyo Comorbidity-Index (CDCI), fall-risk status, tumor size, PET SUV Max, and pathologic information. Freedom-from-RT was evaluated by the Kaplan-Meier method, with duration of AS follow-up recorded from radiographic nodule detection. Post-treatment follow-up was recorded from last radiation treatment date to most recent follow-up CT. VDT calculations used a modified Schwartz equation for exponential growth. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Informed consent was obtained from all patients for being included in the study.

Results
=======

This study included 12 inoperable patients with 15 total lung nodules (Table [1](#TAB1){ref-type="table"}). Median age at diagnosis was 78 (range, 71--85), and median initial KPS was 70. Eleven of 12 patients were deemed to be at high risk for falling and were advised on preventative measures. All nodules were asymptomatic and found incidentally. Biopsy of lesions was performed by both fine needle aspiration and core needle biopsy for all patients, and all patients were staged by PET scan. Endobronchial ultrasound (EBUS) staging was performed for patients with hilar or mediastinal nodes that were enlarged or exhibited high SUV max values on PET scan. Fourteen lesions in 10 patients were staged T1a \[[@REF17]\], the remaining two (lesions 6 & 7) were T1b. All nodules were 90--100% solid. Tumors with a VDT of ≥400 days had a median numerically lower SUV if no biopsy was performed before PET-imaging.

###### Non-operable stage IA lung cancer patients under active surveillance (AS).

AS: Active surveillance; Pt: Patient; Dx: Diagnosis; RUL: Right-upper lobe; RML: Right-middle lobe; RLL: Right-lower lobe; LUL: Left-upper lobe; LLL: Left-lower lobe; Adeno: Adenocarcinoma; SCC: Squamous-cell carcinoma; NEC: Neuroendocrine carcinoma; NSCLC: Non-small cell lung cancer; Non-Bx: Not biopsied; Non-Dx: Biopsy non-diagnostic; OBV: Observation; SABR: Treated with SABR; 3DCRT: Three-dimensional conformal radiation therapy; AS follow-up: Active surveillance follow-up measured from time of nodule detection; ∞: No lesion size change in subsequent CTs; StdDev: Standard deviation; VDT: Volume doubling time.

\*Patients listed in order of decreasing VDT.

\*\*18.9 months median for all patients; 35.1 months median for living patients continuing AS; 21.4 months median of AS time for patients receiving treatment.

  ---------- ---------- ------------- ------- ------------- ------------ -------- --------------- ----------- ------------------------- ----------------------- -------------- --------------------- --------------------------------- ------------------- -------------------------- -------------------------------------
  Pt\*       Sex        Age at dx     CDCI    KPS initial   KPS recent   Lesion   Site            Pathology   Max initial size \[mm\]   Max final size \[mm\]   VDT \[Days\]   Initial PET SUV Max   \#Days PET obtained post biopsy   Management status   AS Follow- up \[Months\]   Follow-up post-treatment \[Months\]
  1          M          73            2       60            0            A        LLL             NEC         16.0                      15.9                    ∞              1.73                  N/A                               OBV                 11.3                       \-
  2          M          78            2       80            60           A        LLL             Adeno       15.0                      15.0                    ∞              1.80                  24                                OBV                 12.0                       \-
  3          F          76            2       80            80           A        RML             NSCLC       19.8                      20.4                    ∞              5.90                  N/A                               3DCRT               6.4                        9.8
  4          F          77            2       90            90           A        LUL             NEC         17.7                      17.9                    3380           6.20                  N/A                               OBV                 19.6                       \-
  5          F          81            2       70            60           A        RLL             Adeno       8.0                       12.6                    1320           3.30                  24                                OBV                 42.3                       \-
  6          M          74            1       60            50           A        RLL             Adeno       14.4                      19.5                    532            1.70                  33                                OBV                 28.5                       \-
  7          M          84            2       60            0            A        RUL             NSCLC       26.0                      30.0                    504            12.10                 26                                OBV                 5.0                        \-
  8          M          82            1       70            70           A        LLL             Adeno       13.7                      18.5                    317            8.20                  N/A                               3DCRT               11.6                       4.2
  9          F          83            1       70            60           A        RUL             Adeno       12.0                      22.2                    242            1.90                  N/A                               SABR                18.1                       16.5
  10         F          71            2       70            70           A        RUL apex        Adeno       12.0                      28.0                    229            4.44                  7                                 SABR                25.2                       22.8
                                                                         B        RUL posterior   Non-Bx      13.0                      16.6                    2700           2.42                  N/A                               OBV                 41.6                       \-
  11         M          85            2       90            70           A        RUL             SCC         25.0                      39.0                    148            5.60                  3                                 3DCRT               20.7                       16.0
                                                                         B        RLL             Non-Bx      8.0                       18.0                    97             2.37                  N/A                               SABR                12.5                       20.7
  12         M          75            1       90            60           A        RML             Adeno       8.0                       16.0                    985            1.07                  11                                OBV                 131.4                      \-
                                                                         B        LUL             Non-Bx      3.0                       12.0                    62             0.97                  N/A                               SABR                21.4                       45.4
  Median     78         2             70      60            N/A          N/A      N/A             13.7        18.4                      504                     3.15           24                    N/A                               18.9\*\*            16.5                       
  Mean       78         N/A           N/A     N/A           N/A          N/A      N/A             14.6        21.7                      540                     4.19           18                    N/A                               27.6                19.3                       
  Range      71 -- 85   1-2           60-90   0-90          N/A          N/A      N/A             3.0-26.0    12.0-40.6                 62-∞                    1.07-12.1      3-33                  N/A                               5.0-131 .4          4.2-45.4                   
  Std Dev    4.7        N/A           N/A     N/A           N/A          N/A      N/A             6.5         8.9                       488                     2.77           10.4                  N/A                               N/A                 N/A                        
  ---------- ---------- ------------- ------- ------------- ------------ -------- --------------- ----------- ------------------------- ----------------------- -------------- --------------------- --------------------------------- ------------------- -------------------------- -------------------------------------

Seven tumors in six patients were treated due to tumor progression; three patients had single nodules and the remaining three patients had two. Median duration of AS for those still continuing CT-surveillance is 35.1 months, range (12--131.4), excluding those deceased (n = 2), on hospice (n = 1), or treated with RT (n = 7). The reason for the long follow-up time for patient 12 is that he initially declined therapy following diagnosis, but then chose AS after the option started being offered in 2014. Follow-up chest CTs were performed at a median interval of four months (range, 2--6). Two of seven treated lesions were not biopsy-proven, but were growing more rapidly than biopsy-proven cancers of the same patient (Figure [1A](#FIG1){ref-type="fig"}, [1D](#FIG1){ref-type="fig"}). The median, one, two and three year patient freedom-from-RT values were 21.4 months (95% CI: 11.6-not reached), 81%, 43%, and 29%, respectively (Figure [2](#FIG2){ref-type="fig"}). Indications for treatment were based on concern from large increases in tumor diameter, given the lack of existing data on a VDT-directed AS approach. Median VDT of nodules treated because of observed tumor growth was 189 days (range, 62--infinite) vs. 1153 days (range, 504--infinite) for untreated nodules. The only patient to request RT before it was encouraged was patient 3, who reported family concerns led to the decision, despite the patient's comfort with AS and an infinite VDT (no growth observed in 6.4 months). SABR involved 50 Gy in five fractions delivered every other day. Although eligible by size criteria for SABR, due to concerns for potential cardiac and chest wall toxicity from the more aggressive SABR fractionation, patients 3, 8, and 11 opted for 15-fraction courses of daily radiation (52--52.5 Gy). Toxicities included grade 1 dermatitis (n = 1) and grade 1 (n = 5) fatigue.

![Patient 12. (A) RML adenocarcinoma, initially 8 x 5 mm. (B) 11.0 years later, measuring 16 x 15 mm (VDT = 985 days); AS continues. (C) Unbiopsied LUL nodule, initially 3 x 3 mm. (D) 21.3 months later, measuring 12 x 9 mm (VDT = 62 days); SABR delivered.\
RML: Right-middle lobe; VDT: Volume doubling time; AS: Active surveillance; LUL: Left-upper lobe; SABR: Stereotactic ablative radiotherapy.](cureus-0010-00000003472-i01){#FIG1}

![Kaplan-Meier estimated survival curve showing freedom-from-RT among the 12 patients. Seven nodules in six patients received RT. Median, one, two and three year patient freedom-from-RT values were 21.4 months (95% CI: 11.6-not reached), 81%, 43%, and 29%, respectively.\
RT: Radiation therapy](cureus-0010-00000003472-i02){#FIG2}

No patient progressed regionally or distantly, and there have been no cancer-related deaths. Due to debilitating cardiovascular disease, patient 2 died during AS (15 months post-nodule detection). Patients 3 and 7 transitioned to hospice during AS; patient 7 has since passed away from congestive heart failure (19 months post-nodule detection).

Discussion
==========

In "Being Mortal," Gawande highlights a patient with a recently discovered pulmonary nodule. After feeling concern regarding a geriatrician's dismissal of the pulmonary nodule, Gawande learned "\...the single most serious threat she faced was not the lung nodule... it was falling \[[@REF18]\]." Similarly, all patients in this series had incidentally discovered lung tumors amidst advanced age and competing comorbidities of larger concern. Coincidently, 92% were deemed high-risk for falls. The primary goals of care for this patient population focused on avoiding any side effects that could result in any loss of independence, and noting the asymptomatic character of their malignancies, AS was elected by the individuals of this group. In the management for early-stage lung cancer in medically inoperable elderly patients, SABR is an oft-elected modality, as it is associated with increased OS compared to no treatment \[[@REF1]\], but those receiving SABR have an expected median OS of just 17.7--29 months, compared to 10 months via observation \[[@REF1],[@REF2]\]. SABR is associated with three-year actuarial regional and distant failure of 8--10% and 9--23%, respectively. Three-year OS and cause-specific survival (CSS) rates are reported at 42--57.5% and 50.4--90%, respectively, indicating many patients die for reasons other than cancer, and, even with treatment, cancer-related fatalities may occur \[[@REF2]\].

Scholten et al. showed CT-monitoring is suitable for persistent sub-solid or partially solid nodules, as they rarely develop into clinically manifesting malignancies unexpectedly \[[@REF16]\]. Our data suggests that preservation of curative potential is possible in an AS program, even for entirely solid nodules. All 15 nodules consisted of 90--100% solid components, with no regional/distant progression at a median AS time of 35.1 months for all living patients. Therefore, we did not find compromise of oncologic outcomes from AS. Survival of patients in this series is comparable to treated patients of other SABR series \[[@REF1],[@REF2]\].

Although SABR has been established as safe and effective for early stage NSCLC, there are still potential side-effects. Kreinbrink et al. did not report any chest wall toxicity, but most tumors were small, dosimetry was favorable, and median follow-up was shorter than median time-to-chest wall toxicity reported by Thibault et al. \[[@REF2],[@REF10]\]. In other series, the incidence of grade 1 and 2 chest wall toxicity has been reported at 25% and 4%, respectively. For osteoporotic elderly patients, Thibault et al. noted a two-year fracture rate \>60%, with events continuing to occur beyond two years \[[@REF10]\]. Following SABR, rates of grade 2 and ≥3 pneumonitis have been reported in up to 20% and 10% of patients, respectively, with even grade 2 toxicities affecting abilities to perform basic activities of daily living (ADL) \[[@REF2]\].

Limitations of this study include its retrospective nature and limited sample size. Not all lesions underwent biopsy, with diagnosis based on PET-avidity and growth, but all patients had at least one pathologically proven lung cancer. Treatment indications were based on a fast diameter-based measurements growth rate and not VDT, given the lack of data to guide a VDT-directed approach.

Despite the noted limitations, this series is valuable as the first report of a potentially effective treatment algorithm, minimizing toxicity while maintaining the benefit of treatment at an early stage. Our data suggests that AS may be a reasonable option for selected stage I NSCLC medically inoperable patients, without compromising outcomes. As SABR is shown to provide a median OS of 17.7--29 months in medically inoperable elderly patients \[[@REF1]\], comparatively, this series has provided a median duration follow-up of 35.1 months for those who elected AS and continuing CT-surveillance. Remarkably, patient 12 has been followed for over 11 years without requiring treatment to the biopsy-proven malignancy in his right-middle lobe (RML), and has had no regional or distant spread of disease. Treatment-related toxicities are reported to be low in the elderly including those up to 90 years old \[[@REF2]\]; however, there is still a risk associated with putting people into treatment, and the pendulum may be swinging towards overtreatment. Despite the low risk, risk of toxicity still exists, which can be ever more significant for those with senescent independence.

The importance of AS appears to be increasing beyond prostate to include breast and thyroid \[[@REF19]\], and we believe this process deserves further evaluation for frail, elderly patients with lung cancer. Our data has formed the basis for a currently open prospective study, where patients are offered SABR versus continued AS based on tumor VDT and size, incorporating a concurrent analysis of biomarkers, quality of life measures, and allowing characterization of outcomes with a larger study population.

Conclusions
===========

Untreated stage I lung cancer generally portends a poor prognosis, however in elderly populations, particularly those with significant comorbidities, treatment decisions must weigh a cancer's aggressiveness with competing risks of death. Selected elderly patients with stage IA lung cancer may benefit from an active surveillance approach. This study included 12 inoperable patients with 15 total lung nodules who underwent AS. Median duration of AS for those still continuing CT-surveillance is 35.1 months. Of significance, no patient progressed regionally or distantly, and there have been no cancer-related deaths.

This series is valuable as the first report of a potentially effective treatment algorithm, minimizing toxicity while maintaining the benefit of treatment at an early stage. Our data suggests that AS may be a reasonable option for selected stage I NSCLC medically inoperable patients, without compromising outcomes.
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